TWST — Twist Bioscience Corp

Nasdaq · Health Care · Biotechnology · CIK 1581280 ·
Last close
$64.87
Market Cap
$4.04B
52W High
$66.06
52W Low
$41.52
ADV30
1,536,119
Next earnings
2026-08-03
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 110,715,000 57,122,000 -38,658,000 -44,021,000 676,214,000 122,670,000 221,120,000
Dec 2025 103,698,000 53,972,000 -33,100,000 -30,507,000 638,085,000 148,591,000 181,990,000
Sep 2025 99,009,000 50,837,000 -29,934,000 -27,138,000 641,861,000 183,049,000 168,903,000
Jun 2025 96,057,000 51,297,000 -30,120,000 20,390,000 643,605,000 201,373,000 165,407,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-55,587,000
Investing CF
$-44,439,000
Financing CF
$11,836,000
CapEx
$-39,553,000
Dividends Paid
Buybacks
$-15,000
EPS Diluted TTM
$-1.33
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,394,106,000
Inventory
$33,515,000
Receivables
$87,448,000
ST Investments
$49,001,000
EBIT TTM
$-131,812,000
Pretax Income TTM
$-80,532,000
Interest Exp TTM
$0
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$409,479,008
EBITDA
$-109,835,000
Free Cash Flow
$-58,482,500
Enterprise Value
$3,710,943,488
Total Cash
$171,671,008
Total Debt
$110,841,000
Shares Out
62,271,314
Trailing EPS
$-1.32
Book Value
$7.32
ROE
-18.2%
ROA
-12.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Sep 2025 376,572,000 -136,259,000 -77,670,000 641,861,000 168,903,000 -47,628,000
Sep 2024 312,974,000 -175,901,000 -208,726,000 614,323,000 141,634,000 -64,094,000
Sep 2023 245,109,000 -206,903,000 -204,618,000 776,403,000 152,971,000 -142,474,000
Sep 2022 203,565,000 -249,021,000 -217,863,000 961,378,000 171,993,000 -124,385,000

TTM Snapshot

Revenues TTM
$170,177,000
NetIncome TTM
$-117,165,000
OpCashFlow TTM
$0
Assets (Latest)
$641,861,000
Forward EPS
$-2.05

Peers — same industry

TickerNameMarket CapLastDaily %
CRSP CRISPR Therapeutics AG $4.98B $51.59
APGE Apogee Therapeutics, Inc. $5.13B $82.81
DNLI Denali Therapeutics Inc. $3.08B $19.38
BEAM Beam Therapeutics Inc. $3.06B $29.79
RLAY Relay Therapeutics, Inc. $3.04B $14.17

News headlines (Yahoo Finance, 1h cache)

Cathie Wood Is Dumping AMD and TSMC Stock. Here's What She's Buying Instead
2026-05-26 13:13 · Yahoo
Twist Bioscience Corporation (TWST) Expands its Clonal Gene Offering to Include Long and Complex Sequences
2026-05-23 04:50 · Yahoo
Cathie Wood trims $3.17M of surging bioscience stock
2026-05-14 04:37 · Yahoo
Assessing Twist Bioscience (TWST) Valuation After Strong Recent Momentum And Mixed Fair Value Signals
2026-05-12 14:15 · Yahoo
DNA Synthesis Market to Reach $30.4 billion, Globally, by 2035 at 18.2% CAGR: Allied Market Research
2026-05-11 17:33 · Yahoo
Twist Bioscience Corporation (TWST) Announces Q2 2026 Financial Results
2026-05-10 23:14 · Yahoo
LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery
2026-05-08 13:08 · Yahoo
Twist Bioscience Corp (TWST) Climbed on Earnings Beat
2026-05-08 12:55 · Yahoo
Twist Bioscience Corp. (TWST) Rallied on Record-Breaking Quarterly Report
2026-05-08 12:49 · Yahoo
Did Twist’s Upbeat Revenue Guidance and Complex Genes Launch Just Shift Twist Bioscience's (TWST) Investment Narrative?
2026-05-08 07:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.